MX2023011873A - Compuestos de oxazepina y sus usos en el tratamiento del cancer. - Google Patents
Compuestos de oxazepina y sus usos en el tratamiento del cancer.Info
- Publication number
- MX2023011873A MX2023011873A MX2023011873A MX2023011873A MX2023011873A MX 2023011873 A MX2023011873 A MX 2023011873A MX 2023011873 A MX2023011873 A MX 2023011873A MX 2023011873 A MX2023011873 A MX 2023011873A MX 2023011873 A MX2023011873 A MX 2023011873A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- cancer
- oxazepine compounds
- compounds
- oxazepine
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 150000000221 oxazepines Chemical class 0.000 title 1
- -1 acyclic oxazepinyl compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021085959 | 2021-04-08 | ||
| PCT/US2022/023573 WO2022216762A1 (en) | 2021-04-08 | 2022-04-06 | Oxazepine compounds and uses thereof in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011873A true MX2023011873A (es) | 2023-10-17 |
Family
ID=81387302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011873A MX2023011873A (es) | 2021-04-08 | 2022-04-06 | Compuestos de oxazepina y sus usos en el tratamiento del cancer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240383915A1 (https=) |
| EP (1) | EP4320132A1 (https=) |
| JP (1) | JP2024513881A (https=) |
| KR (1) | KR20230167386A (https=) |
| CN (1) | CN117083279A (https=) |
| AR (1) | AR125304A1 (https=) |
| AU (1) | AU2022254674A1 (https=) |
| BR (1) | BR112023020773A2 (https=) |
| CA (1) | CA3215949A1 (https=) |
| MX (1) | MX2023011873A (https=) |
| TW (1) | TWI868441B (https=) |
| WO (1) | WO2022216762A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| AU2023231139A1 (en) | 2022-03-11 | 2024-09-05 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| AU2023320914A1 (en) * | 2022-08-11 | 2025-02-27 | Beone Medicines I Gmbh | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2024041573A1 (en) * | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| AU2023363515A1 (en) * | 2022-10-18 | 2025-04-17 | Idience Co., Ltd. | Novel triheterocyclic compounds |
| JP2025535367A (ja) * | 2022-10-19 | 2025-10-24 | ジェネンテック， インコーポレイテッド | ６－アザ部分を含むオキサゼピン化合物およびその使用 |
| TW202430179A (zh) | 2022-11-21 | 2024-08-01 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑 |
| WO2024153180A1 (zh) * | 2023-01-18 | 2024-07-25 | 上海艾力斯医药科技股份有限公司 | 杂环类化合物、其药物组合物及其用途 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| WO2024197503A1 (en) * | 2023-03-27 | 2024-10-03 | Nikang Therapeutics , Inc. | Tricyclic derivatives as kras inhibitors |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN121194980A (zh) * | 2023-05-16 | 2025-12-23 | 和记黄埔医药（上海）有限公司 | 三环类化合物及其用途 |
| CN121605110A (zh) * | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | 取代杂环化合物及其用途 |
| CN121263417A (zh) * | 2023-06-30 | 2026-01-02 | 金橘生物科技公司 | 取代的稠合三环胺化合物及其作为ras抑制剂的用途 |
| CN116903499B (zh) * | 2023-07-11 | 2025-05-30 | 上海应用技术大学 | 无水氟磺酰基二氟乙酸铜盐及其制备方法与应用 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025038936A1 (en) | 2023-08-17 | 2025-02-20 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025096738A1 (en) * | 2023-11-01 | 2025-05-08 | Incyte Corporation | Kras inhibitors |
| WO2025111586A1 (en) | 2023-11-22 | 2025-05-30 | Genentech, Inc. | Polymorphs of and synthetic process for an aza-tetracyclic oxazepine inhibitor of kras-g12d |
| WO2025130912A1 (zh) * | 2023-12-19 | 2025-06-26 | 正大天晴药业集团股份有限公司 | 三并环类化合物及其医药用途 |
| WO2025167948A1 (zh) * | 2024-02-06 | 2025-08-14 | 上海齐鲁制药研究中心有限公司 | 嘧啶并大环类kras抑制剂 |
| WO2025168072A1 (en) * | 2024-02-08 | 2025-08-14 | Beigene (Suzhou) Co., Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JP6832430B2 (ja) * | 2016-08-31 | 2021-02-24 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞代謝過程の阻害剤 |
| EP3621968A1 (en) * | 2017-05-11 | 2020-03-18 | Astrazeneca AB | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| KR102934231B1 (ko) * | 2019-03-05 | 2026-03-06 | 아스트라제네카 아베 | 항암제로 유용한 융합 삼환식 화합물 |
| WO2021063346A1 (zh) * | 2019-09-30 | 2021-04-08 | 上海迪诺医药科技有限公司 | Kras g12c抑制剂及其应用 |
-
2022
- 2022-04-06 JP JP2023561271A patent/JP2024513881A/ja active Pending
- 2022-04-06 WO PCT/US2022/023573 patent/WO2022216762A1/en not_active Ceased
- 2022-04-06 BR BR112023020773A patent/BR112023020773A2/pt unknown
- 2022-04-06 EP EP22719149.1A patent/EP4320132A1/en active Pending
- 2022-04-06 AR ARP220100858A patent/AR125304A1/es unknown
- 2022-04-06 TW TW111113063A patent/TWI868441B/zh active
- 2022-04-06 CN CN202280026974.XA patent/CN117083279A/zh active Pending
- 2022-04-06 CA CA3215949A patent/CA3215949A1/en active Pending
- 2022-04-06 AU AU2022254674A patent/AU2022254674A1/en active Pending
- 2022-04-06 US US18/554,438 patent/US20240383915A1/en active Pending
- 2022-04-06 KR KR1020237037698A patent/KR20230167386A/ko active Pending
- 2022-04-06 MX MX2023011873A patent/MX2023011873A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117083279A (zh) | 2023-11-17 |
| TW202304934A (zh) | 2023-02-01 |
| KR20230167386A (ko) | 2023-12-08 |
| AR125304A1 (es) | 2023-07-05 |
| US20240383915A1 (en) | 2024-11-21 |
| WO2022216762A1 (en) | 2022-10-13 |
| EP4320132A1 (en) | 2024-02-14 |
| CA3215949A1 (en) | 2022-10-13 |
| JP2024513881A (ja) | 2024-03-27 |
| BR112023020773A2 (pt) | 2024-01-30 |
| TWI868441B (zh) | 2025-01-01 |
| AU2022254674A1 (en) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023011873A (es) | Compuestos de oxazepina y sus usos en el tratamiento del cancer. | |
| CO2024017330A2 (es) | Compuestos aza-tetracíclicos de oxazepina y usos de los mismos | |
| MX2023009135A (es) | Compuestos de oxazepina tetraciclica y usos de estos. | |
| CL2020002914A1 (es) | Métodos y composiciones para tratar el cáncer | |
| AR120147A1 (es) | Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco | |
| CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
| MX2021007468A (es) | Compuestos que participan en la union cooperativa y usos de los mismos. | |
| CO2019008783A2 (es) | Compuestos dinucleotidos ciclicos para el tratamiento del cancer | |
| CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
| CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
| MX2025002382A (es) | Anticuerpos antagonistas anti-tigit y anti-pd-l1 y usos de los mismos para el tratamiento del cancer | |
| CO2019005909A2 (es) | Anticuerpos y polipéptidos dirigidos contra cd127 | |
| CO2025011369A2 (es) | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos | |
| MX2023008327A (es) | Anticuerpos inmunomoduladores de anticuerpo-farmaco. | |
| AR104664A1 (es) | Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6) | |
| MX2021005395A (es) | Terapia del cáncer con células inmunitarias anti-liv1. | |
| CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
| MX2018010993A (es) | Derivados de icariina e icaritina. | |
| CL2022000522A1 (es) | Lurbinectedina en el tratamiento del mesotelioma maligno. | |
| CL2023003562A1 (es) | Anticuerpos y composiciones anti-nkg2a | |
| CL2025001142A1 (es) | Anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, métodos terapéuticos y sus usos | |
| CO2024015381A2 (es) | Conjugados anticuerpo-fármaco 5t4 y usos de los mismos | |
| MX2019010981A (es) | Terapias de combinacion para el tratamiento de cancer de mama. | |
| AR121881A1 (es) | Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos | |
| MX2022011845A (es) | Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2. |